Faculty Profile: Adam Olszewski

Adam Olszewski
Adam Olszewski
Assistant Profesor of Medicine
Memorial Hospital of Rhode Island
Work: 401-729-2700
My primary research interest involves comparative outcome analysis using registry and administrative databases such as SEER/SEER-Medicare and NCDB.
I am interested in advancing the methods for evaluation of treatment interventions in oncology using such population-based data, while overcoming the inherent bias of non-randomized studies related to their retrospective nature and limited clinical validation.

Biography

I received my MD diploma from the Medical University of Warsaw in 1999 and completed my postgraduate training at St. Luke's-Roosevelt Hospital Center in New York.
I joined Memorial Hospital of Rhode Island Cancer Center in 2010, where I work as a clinical hematologist/oncologist and teacher.
My research interests involve clinical trials developed in the framework of the Brown University Oncology Group (BrUOG), as well as healthcare outcome research using registry and administrative databases such as SEER/SEER-Medicare and NCDB.
I am particularly interested in advancing the methodology for evaluation of treatment interventions using the vast amount of information in population-derived data, while overcoming the inherent bias of such analyses related to their retrospective nature and limited clinical validation.

Grants and Awards

Academic Proficiency Award, years 2 through 6, The Medical University of Warsaw, Poland, 1994-1999
W.I.S.E. (Worldwide Insitute Supporting Exchange) Scholarship, Worcester, MA, 2000
Award for Outstanding Excellence in Primary Care, St. Luke's-Roosevelt Hospital Center, New York, 2003
Chief Fellow Appointment, St. Luke's-Roosevelt Hospital Center, New York, 2005

Affiliations


  • American Society of Clinical Oncology

  • American Society of Hematology

  • American Society of Clinical Oncology, Scientific Program Committee (Cancer Prevention/Epidemiology track)

Teaching Experience

Problem-based Learning
Clinical Teaching Rounds, Memorial Hospital of Rhode Island
Career Mentorship, Medical Residents PGY1-PGY3, Memorial Hospital of Rhode Island
Research Mentorship, Brown University Medical Students
Internal Medicine Noon Conference Lectures

Selected Publications

  • 1. Olszewski AJ, Desai A. Radiation Therapy Administration and Survival in Stage I/II Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. Int J Radiat Oncol Biol Phys. 2014 Jan 7. pii: S0360-3016(13)03583-9. doi: 10.1016/j.ijrobp.2013.11.225 (2014)
  • Olszewski AJ, Migdady Y, Boolbol S, Klein P, Boachie-Adjei K, Sakr B, et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study. Breast Cancer Research and Treatment. 2013:138(1):215-23. doi: 10.1007/s10549-013-2423-3 (2013)
  • Olszewski AJ, Castillo JJ. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-Medicare database. Annals of Oncology 2013 May;24(5):1352-9.doi: 10.1093/annonc/mds644 (2013)
  • Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013 Jul 30. doi: 10.1002/cncr.28264. (2013)
  • Olszewski AJ, Ali S.Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma. Ann Hematol. 2013 Sep 22. doi:10.1007/s00277-013-1900-4 (2013)
  • Ali S, Olszewski AJ. Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: a population-based study. Leuk Lymphoma. 2013 Sep 25. doi:10.3109/10428194.2013.847938 (2013)
  • Bishop KD, Olszewski AJ. Epidemiology and survival outcomes of ocular and mucosal melanomas: A population-based analysis. Int J Cancer. 2013 Nov 22. doi: 10.1002/ijc.28625. (2013)
  • 2. Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: An analysis of the surveillance, epidemiology and end results database. Am J Hematol. 2013 Nov 23. doi: 10.1002/ajh.23638. (2013)
  • Olszewski AJ. Survival outcomes with and without splenectomy in splenic marginal zone lymphoma. Am J Hematol. 2012 Jul 23. doi: 10.1002/ajh.23314. (2012)
  • Olszewski AJ, Castillo JJ. Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer 2013 Feb 1;119(3):629-38 doi: 10.1002/cncr.27773. (2012)
  • Migdady Y, Olszewski AJ. Evaluation of incidental neutropenia in a multi-ethnic setting. Int J Lab Hematol 2013, 35: e6–e8. DOI: 10.1111/ijlh.12016. (2012)
  • Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS. Phase I Study of Oxaliplatin in Combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leucovorin (G-FLIE) in Patients with Metastatic Solid Tumors Including Adenocarcinoma of the Pancreas. J Gastrointest Cancer. 2012 Dec 4. doi: 10.1007/s12029-012-9466-2 (2012)
  • Gavini A, Telang GH, Olszewski AJ. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia. Int J Hematol 2012 Mar;95(3):311-4. DOI: 10.1007/s12185-012-1012-2 (2011)
  • Olszewski AJ, Grossbard ML, Kozuch P. The Horizon of Antiangiogenic Therapy for Colorectal Cancer. Oncology (Williston Park): March 2005:19(3): 297. (2005)
  • Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from rituximab. Science STKE. 2004 Jul 6;2004(241):PE30. (2004)
  • Li M, Ona VO, Guegan C, Chen M, Jackson-Lewis V, Andrews LJ, Olszewski AJ, Stieg PE, Lee JP, Przedborski S, Friedlander RM. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science. 2000 Apr 14;288(5464):335-9. DOI: 10.1126/science.288.5464.335 (2000)